Page 2 of 2: [  1  2 ]

#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
101	5	66	101 2006 CANCER CELL 10 (1): 65-75 Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia	0	0
102	1	54	102 2006 CANCER CELL 10 (1): 77-87 Kovacic B; Stoiber D; Moriggl R; Weisz E; Ott RG; et al. STAT1 acts as a tumor promoter for leukemia development	0	0
103	2	200	103 2006 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 57 (2): 145-164 Walz C; Sattler M Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)	0	1
104	1	148	104 2006 CURRENT CANCER DRUG TARGETS 6 (2): 107-121 Klampfer L Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs	0	0
105	1	46	105 2006 CURRENT OPINION IN ONCOLOGY 18 (1): 62-68 Taki T; Taniwaki M Chromosomal translocations in cancer and their relevance for therapy	0	0
106	3	198	106 2006 CURRENT PHARMACEUTICAL BIOTECHNOLOGY 7 (3): 185-198 Oveland E; Fladmark KE; Wergeland L; Gjertsen BT; Hovland R Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies	0	0
107	5	20	107 2006 EUROPEAN JOURNAL OF HAEMATOLOGY 77 (1): 57-60 Thurmes PJ; Steensma DP Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis	0	0
108	8	23	108 2006 EUROPEAN JOURNAL OF HAEMATOLOGY 77 (3): 210-216 Heller PG; Lev PR; Salim JP; Kornblihtt LI; Goette NP; et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status	0	0
109	2	34	109 2006 GASTROENTEROLOGY 130 (7): 2031-2038 Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome	0	0
110	2	72	110 2006 GROWTH FACTORS 24 (1): 89-95 Ingley E; Klinken SP Cross-regulation of JAK and Src kinases	0	0
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
111	19	34	111 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (2): 159-161 Cazzola M; Passamonti F Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders	0	0
112	4	36	112 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (2): 169-175 Arellano-Rodrigo E; Alvarez-Larran A; Reverter JC; Villamor N; Colomer D; et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status	3	3
113	1	22	113 2006 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 91 (8): 1100-1104 Vassiliou GS; Campbell PJ; Li J; Roberts I; Swanton S; et al. An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation	0	0
114	2	115	114 2006 HEMATOLOGICAL ONCOLOGY 24 (2): 56-63 Reilly JT Idiopathic myelofibrosis: pathogenesis to treatment	0	0
115	5	15	115 2006 HUMAN PATHOLOGY 37 (4): 500-502 Tzankov A; Heiss S Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) transtocation - reply	0	0
116	4	42	116 2006 JOURNAL OF BIOLOGICAL CHEMISTRY 281 (26): 18177-18183 Walz C; Crowley BJ; Hudon HE; Gramlich JL; Neuberg DS; et al. Activated Jak2 with the V617F point mutation promotes G(1)/S phase transition	0	0
117	1	45	117 2006 JOURNAL OF IMMUNOLOGY 176 (11): 6425-6433 Wagner-Ballon O; Chagraoui H; Prina E; Tulliez M; Milon G; et al. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin	0	0
118	2	18	118 2006 JOURNAL OF MOLECULAR DIAGNOSTICS 8 (2): 170-177 Bock O; Busche G; Koop C; Schroter S; Buhr T; et al. Detection of the single hotspot mutation in the JH2 pseuclokinase domain of janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders	2	2
119	9	18	119 2006 JOURNAL OF MOLECULAR DIAGNOSTICS 8 (3): 299-304 Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; et al. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases	0	0
120	7	10	120 2006 JOURNAL OF MOLECULAR DIAGNOSTICS 8 (3): 330-334 Lay M; Mariappan R; Gotlib J; Dietz L; Sebastian S; et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis	0	0
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
121	1	27	121 2006 LEUKEMIA 20 (1): 55-60 Cervantes F; Alvarez-Larran A; Arellano-Rodrigo E; Granell M; Domingo A; et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution	0	0
122	3	8	122 2006 LEUKEMIA 20 (1): 168-171 McClure R; Mai M; Lasho T Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders	2	3
123	7	69	123 2006 LEUKEMIA 20 (2): 200-205 De Keersmaecker K; Cools J Chronic myeloproliferative disorders: a tyrosine kinase tale	2	4
124	2	8	124 2006 LEUKEMIA 20 (2): 350-353 James C; Delhommeau F; Marzac C; Teyssandier I; Le Couedic JP; et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis	4	5
125	5	22	125 2006 LEUKEMIA 20 (3): 471-476 Quentmeier H; Macleod RAF; Zaborski M; Drexler HG JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders	1	1
126	7	10	126 2006 LEUKEMIA 20 (3): 534-535 Vizmanos JL; Ormazabal C; Larrayoz MJ; Cross NCP; Calasanz MJ JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients	1	1
127	5	9	127 2006 LEUKEMIA 20 (4): 736-737 Bellosillo B; Besses C; Florensa L; Sole F; Serrano S JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders	2	2
128	11	63	128 2006 LEUKEMIA 20 (6): 971-978 Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained	1	1
129	12	28	129 2006 LEUKEMIA 20 (6): 1055-1060 Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis	1	1
130	2	7	130 2006 LEUKEMIA 20 (6): 1168-1169 Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; et al. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation	0	0
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
131	7	9	131 2006 LEUKEMIA 20 (7): 1315-1316 Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martinez L; et al. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis	0	0
132	4	8	132 2006 LEUKEMIA 20 (7): 1319-1321 Ingram W; Lea NC; Cervera J; Germing U; Fenaux P; et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow	0	0
133	5	143	133 2006 LEUKEMIA & LYMPHOMA 47 (2): 177-194 Nelson ME; Steensma DP JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?	2	5
134	2	7	134 2006 LEUKEMIA & LYMPHOMA 47 (2): 313-314 Lee JW; Soung YH; Kim SY; Nam SW; Park WS; et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas	2	2
135	5	181	135 2006 LEUKEMIA & LYMPHOMA 47 (3): 381-396 Thiele J; Kvasnicka HM A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders	2	4
136	20	34	136 2006 LEUKEMIA RESEARCH 30 (6): 739-744 Tefferi A; Pardanani A Mutation screening for JAK2(V617F): When to order the test and how to interpret the results	1	2
137	2	363	137 2006 MAYO CLINIC PROCEEDINGS 81 (1): 104-130 Steensma DP; Bennett JM The myelodysplastic syndromes: Diagnosis and treatment	0	2
138	7	173	138 2006 MAYO CLINIC PROCEEDINGS 81 (4): 553-563 Tefferi A; Elliot MA; Pardanani A Atypical myeloproliferative disorders: Diagnosis and management	0	0
139	1	79	139 2006 MOLECULAR AND CELLULAR BIOLOGY 26 (11): 4052-4062 Mazurkiewicz-Munoz AM; Argetsinger LS; Kouadio JLK; Stensballe A; Jensen ON; et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor	0	1
140	2	21	140 2006 NEW ENGLAND JOURNAL OF MEDICINE 354 (20): 2166-2175 Yachimski PS; Chung RT; Sahani DV; Amrein PC; Misdraji J; et al. A 46-year-old woman with sudden onset of abdominal distention - Budd-Chiari syndrome, with centrilobular hepatocellular necrosis, sinusoidal dilatation, congestion, and red-cell extravasation consistent with the presence of venous outflow obstruction. Heterozygosity for factor V Leiden. V617F mutation in JAK2.	0	1
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
141	1	15	141 2006 ONCOGENE 25 (9): 1434-1436 Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias	2	4
142	1	51	142 2006 ONCOGENE 25 (33): 4573-4584 Joliot V; Cormier F; Medyouf H; Alcalde H; Ghysdael J Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis	0	0
143	1	19	143 2006 PATHOLOGIE BIOLOGIE 54 (4): 182-184 Berger R A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders	0	0
144	1	98	144 2006 PHARMACOGENOMICS 7 (4): 597-612 Ma PC; Zhang XD; Wang ZHJ High-throughput mutational analysis of the human cancer genome	0	0
145	8	36	145 2006 PLOS MEDICINE 3 (7): Art. No. E270 Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; et al. MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia	0	0
146	2	39	146 2006 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 103 (16): 6224-6229 Jamieson CHM; Gotlib J; Durocher JA; Chao MP; Mariappan MR; et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation	2	2
147	9	47	147 2006 REVUE DE MEDECINE INTERNE 27 (6): 473-477 Marie I; Herve F Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy	0	0
148	24	185	148 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 174-207 Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: Therapeutic implications	2	3
149	1	43	149 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 208-218 Briere JB Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: Diagnosis and management	0	0
150	10	148	150 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 219-230 Thiele J; Kvasnicka HM Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders	0	1
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
151	4	74	151 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 251-259 Landolfi R; Di Gennaro L; Novarese L; Patrono C Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: Current insights and rationale for future studies	0	0
152	2	51	152 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 267-275 Lengfelder E; Merx K; Hehlmann R Diagnosis and therapy of polycythemia vera	0	0
153	2	35	153 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (3): 283-288 Harrison CN Management of essential thrombocythemia: Implications of the Medical Research Council Primary Thrombocythemia 1 trial	0	1
154	19	229	154 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 307-340 Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders	0	0
155	28	69	155 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 341-351 Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients	0	0
156	11	129	156 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 381-398 Bellucci S; Michiels JJ The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia	0	0
157	3	41	157 2006 SEMINARS IN THROMBOSIS AND HEMOSTASIS 32 (4): 417-421 Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; et al. Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia	0	0

Page 2 of 2: [  1  2 ]
Generated by HistCite 2006.08.14